Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $5.2 million.

  • Adma Biologics' Change in Inventory rose 16496.44% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 18630.97%. This contributed to the annual value of -$2.7 million for FY2024, which is 12774.78% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Change in Inventory is $5.2 million, which was up 16496.44% from $19.3 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Change in Inventory peaked at $19.3 million during Q2 2025, and registered a low of -$8.0 million during Q3 2024.
  • Over the past 5 years, Adma Biologics' median Change in Inventory value was $5.2 million (recorded in 2025), while the average stood at $6.1 million.
  • Its Change in Inventory has fluctuated over the past 5 years, first skyrocketed by 257152.76% in 2023, then plummeted by 69947.6% in 2024.
  • Over the past 5 years, Adma Biologics' Change in Inventory (Quarter) stood at $10.6 million in 2021, then tumbled by 96.54% to $366457.0 in 2022, then surged by 2571.53% to $9.8 million in 2023, then plummeted by 116.0% to -$1.6 million in 2024, then surged by 432.25% to $5.2 million in 2025.
  • Its Change in Inventory was $5.2 million in Q3 2025, compared to $19.3 million in Q2 2025 and $2.0 million in Q1 2025.